Successful Treatment in Children with Hodgkin Lymphoma in Greece; A 20-Year Experience in a Single Institution

Table 5

Prognostic factors for the outcome.

	Patients	%	%			𝑃
			DFS	EFS	OS	DFS	EFS	OS
Age (years)
≤8	9	15.5	77.8	66.7	100	ns	ns	ns
>8	49	84.5	91.8	89.8	98
Gender
Boys	35	60	88.6	85.7	100	ns	ns	ns
Girls	23	40	91.3	87	95.7
Stage
I	7	12	100	85.7	100	ns	ns	ns
II	25	43	92	92	96
III	15	26	93.3	86.7	100
IV	11	19	72.7	72.7	100
Histologic subtype
Mixed cellularity	13	22	92.3	92.3	100	ns	ns	ns
Lymphopenic depletion	1	2	100	100	100
Lymphocytic predominant	4	7	75	75	100
Nodular sclerosis	40	69	90	85	97.5
B-symptoms
Present	18	31	94.4	94.4	100	ns	ns	ns
Absent	40	69	87.5	82.5	97.5
Mediastinum
Great widening	12	21	91.7	83.3	100	ns	ns	ns
Intermediate widening	33	57	87.9	87.9	97
Normal	13	22	92.3	84.6	100
White blood cells (×10^3/mm^3)*
≤10.4	29	51	93.1	89.7	100	ns	ns	ns
>10.4	28	49	89.3	85.7	96.4
Hemoglobin (g/dL)*
≤11	29	51	89.6	82.8	96.5	ns	ns	ns
>11	28	49	92.9	92.9	100
ESR (mm 1st h)*
≤63	29	51	93.1	89.7	100	ns	ns	ns
>63	28	49	89.3	85.7	96.4

*no values for one patient.